

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/A2A2364BD0BCEN.html>

Date: March 2022

Pages: 60

Price: US\$ 3,250.00 (Single User License)

ID: A2A2364BD0BCEN

Abstracts

Acute lymphocytic/lymphoblastic leukemia (ALL) is a type of cancer that develops from immature lymphocytes. “Acute” here indicates leukemia that quickly progresses and spreads across the body.

This report contains market size and forecasts of Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics in Global, including the following market information:

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics market was valued at 1625.7 million in 2021 and is projected to reach US\$ 2197.9 million by 2028, at a CAGR of 4.4% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Hyper-CVAD Regimen Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics include AMGEN, INC, BRISTOL-MYERS SQUIBB COMPANY, ERYTECH PHARMA, LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.),

NOVARTIS AG, PFIZER, INC, RARE DISEASE THERAPEUTICS, INC, SANOFI and SPECTRUM PHARMACEUTICALS, INC and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Segment Percentages, by Type, 2021 (%)

Hyper-CVAD Regimen

Linker Regimen

Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)

Targeted Drugs & Immunotherapy

CALGB 8811 Regimen

Oncaspar

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Segment Percentages, by Application, 2021 (%)

Pediatrics

Adults

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics

revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AMGEN, INC

BRISTOL-MYERS SQUIBB COMPANY

ERYTECH PHARMA

LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)

NOVARTIS AG

PFIZER, INC

RARE DISEASE THERAPEUTICS, INC

SANOFI

SPECTRUM PHARMACEUTICALS, INC

TAKEDA PHARMACEUTICAL COMPANY LIMITED

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL ACUTE LYMPHOCYTTIC/LYMPHOBLASTIC LEUKEMIA (ALL) THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Players in Global Market
- 3.2 Top Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Companies Ranked by Revenue
- 3.3 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Companies in Global Market, by Revenue in 2021

3.5 Global Companies Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics
Product Type

3.6 Tier 1, Tier 2 and Tier 3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
Therapeutics Players in Global Market

3.6.1 List of Global Tier 1 Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Acute Lymphocytic/Lymphoblastic Leukemia
(ALL) Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
Therapeutics Market Size Markets, 2021 & 2028

4.1.2 Hyper-CVAD Regimen

4.1.3 Linker Regimen

4.1.4 Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)

4.1.5 Targeted Drugs & Immunotherapy

4.1.6 CALGB 8811 Regimen

4.1.7 Oncaspar

4.2 By Type - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics
Revenue & Forecasts

4.2.1 By Type - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
Therapeutics Market Size, 2021 & 2028

5.1.2 Pediatrics

5.1.3 Adults

5.2 By Application - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue, 2017-2028

6.3.2 US Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.3.3 Canada Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.3.4 Mexico Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue, 2017-2028

6.4.2 Germany Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.4.3 France Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.4.4 U.K. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.4.5 Italy Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.4.6 Russia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market

Size, 2017-2028

6.4.7 Nordic Countries Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Market Size, 2017-2028

6.4.8 Benelux Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue, 2017-2028

6.5.2 China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.5.3 Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.5.4 South Korea Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.5.6 India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, 2017-2028

6.6.2 Brazil Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.6.3 Argentina Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, 2017-2028

6.7.2 Turkey Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.7.3 Israel Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

6.7.5 UAE Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AMGEN, INC

7.1.1 AMGEN, INC Corporate Summary

7.1.2 AMGEN, INC Business Overview

7.1.3 AMGEN, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings

7.1.4 AMGEN, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)

7.1.5 AMGEN, INC Key News

7.2 BRISTOL-MYERS SQUIBB COMPANY

7.2.1 BRISTOL-MYERS SQUIBB COMPANY Corporate Summary

7.2.2 BRISTOL-MYERS SQUIBB COMPANY Business Overview

7.2.3 BRISTOL-MYERS SQUIBB COMPANY Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings

7.2.4 BRISTOL-MYERS SQUIBB COMPANY Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)

7.2.5 BRISTOL-MYERS SQUIBB COMPANY Key News

7.3 ERYTECH PHARMA

7.3.1 ERYTECH PHARMA Corporate Summary

7.3.2 ERYTECH PHARMA Business Overview

7.3.3 ERYTECH PHARMA Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings

7.3.4 ERYTECH PHARMA Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)

7.3.5 ERYTECH PHARMA Key News

7.4 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)

7.4.1 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Corporate Summary

7.4.2 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Business Overview

7.4.3 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings

7.4.4 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)

7.4.5 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Key News

7.5 NOVARTIS AG

7.5.1 NOVARTIS AG Corporate Summary

- 7.5.2 NOVARTIS AG Business Overview
- 7.5.3 NOVARTIS AG Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings
- 7.5.4 NOVARTIS AG Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)
- 7.5.5 NOVARTIS AG Key News
- 7.6 PFIZER, INC
 - 7.6.1 PFIZER, INC Corporate Summary
 - 7.6.2 PFIZER, INC Business Overview
 - 7.6.3 PFIZER, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings
 - 7.6.4 PFIZER, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)
 - 7.6.5 PFIZER, INC Key News
- 7.7 RARE DISEASE THERAPEUTICS, INC
 - 7.7.1 RARE DISEASE THERAPEUTICS, INC Corporate Summary
 - 7.7.2 RARE DISEASE THERAPEUTICS, INC Business Overview
 - 7.7.3 RARE DISEASE THERAPEUTICS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings
 - 7.7.4 RARE DISEASE THERAPEUTICS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)
 - 7.7.5 RARE DISEASE THERAPEUTICS, INC Key News
- 7.8 SANOFI
 - 7.8.1 SANOFI Corporate Summary
 - 7.8.2 SANOFI Business Overview
 - 7.8.3 SANOFI Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings
 - 7.8.4 SANOFI Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)
 - 7.8.5 SANOFI Key News
- 7.9 SPECTRUM PHARMACEUTICALS, INC
 - 7.9.1 SPECTRUM PHARMACEUTICALS, INC Corporate Summary
 - 7.9.2 SPECTRUM PHARMACEUTICALS, INC Business Overview
 - 7.9.3 SPECTRUM PHARMACEUTICALS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings
 - 7.9.4 SPECTRUM PHARMACEUTICALS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)
 - 7.9.5 SPECTRUM PHARMACEUTICALS, INC Key News
- 7.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED

- 7.10.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED Corporate Summary
- 7.10.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED Business Overview
- 7.10.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Major Product Offerings
- 7.10.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global Market (2017-2022)
- 7.10.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Opportunities & Trends in Global Market
- Table 2. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Drivers in Global Market
- Table 3. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Restraints in Global Market
- Table 4. Key Players of Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics in Global Market
- Table 5. Top Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Type
- Table 9. List of Global Tier 1 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. AMGEN, INC Corporate Summary

Table 31. AMGEN, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Offerings

Table 32. AMGEN, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. BRISTOL-MYERS SQUIBB COMPANY Corporate Summary

Table 34. BRISTOL-MYERS SQUIBB COMPANY Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Offerings

Table 35. BRISTOL-MYERS SQUIBB COMPANY Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. ERYTECH PHARMA Corporate Summary

Table 37. ERYTECH PHARMA Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Offerings

Table 38. ERYTECH PHARMA Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)

Corporate Summary

Table 40. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Offerings

Table 41. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. NOVARTIS AG Corporate Summary

Table 43. NOVARTIS AG Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Product Offerings

Table 44. NOVARTIS AG Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. PFIZER, INC Corporate Summary

Table 46. PFIZER, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Product Offerings

Table 47. PFIZER, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL)

Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 48. RARE DISEASE THERAPEUTICS, INC Corporate Summary

Table 49. RARE DISEASE THERAPEUTICS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Offerings

Table 50. RARE DISEASE THERAPEUTICS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 51. SANOFI Corporate Summary

Table 52. SANOFI Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Offerings

Table 53. SANOFI Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 54. SPECTRUM PHARMACEUTICALS, INC Corporate Summary

Table 55. SPECTRUM PHARMACEUTICALS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Offerings

Table 56. SPECTRUM PHARMACEUTICALS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 57. TAKEDA PHARMACEUTICAL COMPANY LIMITED Corporate Summary

Table 58. TAKEDA PHARMACEUTICAL COMPANY LIMITED Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product Offerings

Table 59. TAKEDA PHARMACEUTICAL COMPANY LIMITED Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Segment by Type in 2021

Figure 2. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Segment by Application in 2021

Figure 3. Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue in 2021

Figure 8. By Type - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share, 2017-2028

Figure 9. By Application - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share, 2017-2028

Figure 10. By Region - Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share, 2017-2028

Figure 11. By Country - North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share, 2017-2028

Figure 12. US Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share, 2017-2028

Figure 16. Germany Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 17. France Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. AMGEN, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. BRISTOL-MYERS SQUIBB COMPANY Acute Lymphocytic/Lymphoblastic

Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. ERYTECH PHARMA Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. NOVARTIS AG Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. PFIZER, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. RARE DISEASE THERAPEUTICS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. SANOFI Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. SPECTRUM PHARMACEUTICALS, INC Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. TAKEDA PHARMACEUTICAL COMPANY LIMITED Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/A2A2364BD0BCEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A2A2364BD0BCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

